Alterity Therapeutics Limited (PRNAF) Annual Income Statement ()
PRNAF Quarterly Financials ()
Frequently Asked Questions About Alterity Therapeutics Limited (PRNAF) Stock
Alterity Therapeutics Limited's (PRNAF) last reported annual revenue was USD 4.02 Million.
Alterity Therapeutics Limited's (PRNAF) annual revenue growth rate based on the revenue reported in the past 5 years is : 105.93%
Alterity Therapeutics Limited's(PRNAF) is not profitable as of its last reported annual financials.
The net profit margin for Alterity Therapeutics Limited's(PRNAF) from its laster reported year is -475.79%
The return on equity (ROE) for Alterity Therapeutics Limited's(PRNAF) from its last reported annual financials is : -104.47%
The return on assets (ROA) for Alterity Therapeutics Limited's(PRNAF) from its last reported annual financials is : -52.66%
The return on invested capital (ROIC) for Alterity Therapeutics Limited's(PRNAF) from its last reported annual financials is : -107.33%
The Debt to Equity ratio for Alterity Therapeutics Limited's(PRNAF) from its last reported annual financials is : 0.00%
The dividend yield for Alterity Therapeutics Limited's(PRNAF) from its laster reported year is 0.00%
Alterity Therapeutics Limited's(PRNAF) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PRNAF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
